2月8日，信达生物（01801.HK）宣布与跨国药企礼来公司达成全球战略合作，双方将共同致力于肿瘤学和免疫学领域新药的研发与商业化。根据协议条款，信达生物将获得3.5亿美元的首付款，并有资格基于未来特定研发进展、监管审批及商业里程碑，获得最高约85亿美元的潜在额外付款。
此次合作标志着两家公司在创新药物全球开发战略上的深度协同。通过整合信达生物在抗体药物研发方面的技术优势与礼来在全球临床开发和商业化网络的资源，双方计划加速多个创新疗法的开发进程，覆盖肿瘤免疫治疗等前沿领域。
这一战略协作不仅为信达生物带来可观的短期资金支持，更为其创新管线的全球化布局提供了重要契机。若后续里程碑顺利达成，累计付款规模有望突破90亿美元，成为近年来中国生物科技企业与跨国药企之间金额最高的合作项目之一。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.